Last mentioned: Mar 18, 2026
2025 Earnings Release
BioVersys officially reports 2025 financial results and corporate highlights.
AlpE Phase 2b Milestone
First patient dosed in the Phase 2b clinical trial of AlpE for pulmonary tuberculosis.
Reporting Announcement
Company announces date for full-year 2025 results and business update.
Fiscal Year End
BioVersys concludes its 2025 fiscal year with key pipeline advancements.
BioVersys AG reported its full-year 2025 financial results, highlighting the successful transition of its lead candidate AlpE into Phase 2b clinical trials for pulmonary tuberculosis. The company's progress underscores its leadership in the antimicrobial resistance (AMR) space as it moves toward late-stage clinical validation.
BioVersys AG reported its full-year 2025 financial results, highlighting significant clinical progress for its lead antimicrobial candidates and a stable cash position. The Swiss biotech successfully advanced its AlpE program into Phase 2b trials, reinforcing its leadership in the fight against multi-drug resistant infections.